Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaJohn F. Seymour, Arnon P. Kater, Thomas J. Kipps et al.|New England Journal of Medicine|2018Cited by 907
From the bench to the bedside: ways to improve rituximab efficacyGuillaume Cartron, Philippe Solal‐Céligny|Blood|2004Cited by 518
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trialAndrew D. Zelenetz, Franck Morschhauser, Gilles Salles et al.|Blood|2019Cited by 136
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL studyFranck Morschhauser, Loretta J. Nastoupil, Kirit M. Ardeshna et al.|Nature Medicine|2024Cited by 127
Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysisMassimo Federico, Bertrand Coiffier, María Dolores Caballero Barrigón et al.|The Lancet Haematology|2018Cited by 116